Cargando…

Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke

BACKGROUND: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelé, Patrick, Vingtdeux, Valérie, Potey, Camille, Drobecq, Hervé, Ghestem, Antoine, Melnyk, Patricia, Buée, Luc, Sergeant, Nicolas, Bordet, Régis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061923/
https://www.ncbi.nlm.nih.gov/pubmed/24944524
http://dx.doi.org/10.1186/1477-5956-12-24
_version_ 1782321572574396416
author Gelé, Patrick
Vingtdeux, Valérie
Potey, Camille
Drobecq, Hervé
Ghestem, Antoine
Melnyk, Patricia
Buée, Luc
Sergeant, Nicolas
Bordet, Régis
author_facet Gelé, Patrick
Vingtdeux, Valérie
Potey, Camille
Drobecq, Hervé
Ghestem, Antoine
Melnyk, Patricia
Buée, Luc
Sergeant, Nicolas
Bordet, Régis
author_sort Gelé, Patrick
collection PubMed
description BACKGROUND: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechanism may be of interest for future therapeutic purposes. To this end, we have used our well established rodent model of ischemia-reperfusion pre-treated or not with fenofibrate or atorvastatin and performed a differential proteomics analyses of the brain and analysed the protein markers which levels returned to “normal” following pre-treatments with PPARα agonists. RESULTS: In order to identify potential therapeutic targets positively modulated by pre-treatment with the PPARα agonists, two-dimensional gel electrophoresis proteome profiles between control, ischemia-reperfusion and pre-treated or not, were compared. The polypeptide which expression was altered following ischemia – reperfusion but whose levels remain unchanged after pre-treatment were characterized by mass spectrometry and further investigated by Western-blotting and immunohistochemistry. A series of 28 polypeptides were characterized among which the protein disulfide isomerase reduction – a protein instrumental to the unfolded protein response system - was shown to be reduced following PPARα agonists treatment while it was strongly increased in ischemia-reperfusion. CONCLUSIONS: Pre-treatment with PPARα agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARα agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARα known-regulated targets.
format Online
Article
Text
id pubmed-4061923
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40619232014-06-19 Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke Gelé, Patrick Vingtdeux, Valérie Potey, Camille Drobecq, Hervé Ghestem, Antoine Melnyk, Patricia Buée, Luc Sergeant, Nicolas Bordet, Régis Proteome Sci Research BACKGROUND: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechanism may be of interest for future therapeutic purposes. To this end, we have used our well established rodent model of ischemia-reperfusion pre-treated or not with fenofibrate or atorvastatin and performed a differential proteomics analyses of the brain and analysed the protein markers which levels returned to “normal” following pre-treatments with PPARα agonists. RESULTS: In order to identify potential therapeutic targets positively modulated by pre-treatment with the PPARα agonists, two-dimensional gel electrophoresis proteome profiles between control, ischemia-reperfusion and pre-treated or not, were compared. The polypeptide which expression was altered following ischemia – reperfusion but whose levels remain unchanged after pre-treatment were characterized by mass spectrometry and further investigated by Western-blotting and immunohistochemistry. A series of 28 polypeptides were characterized among which the protein disulfide isomerase reduction – a protein instrumental to the unfolded protein response system - was shown to be reduced following PPARα agonists treatment while it was strongly increased in ischemia-reperfusion. CONCLUSIONS: Pre-treatment with PPARα agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARα agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARα known-regulated targets. BioMed Central 2014-05-06 /pmc/articles/PMC4061923/ /pubmed/24944524 http://dx.doi.org/10.1186/1477-5956-12-24 Text en Copyright © 2014 Gelé et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gelé, Patrick
Vingtdeux, Valérie
Potey, Camille
Drobecq, Hervé
Ghestem, Antoine
Melnyk, Patricia
Buée, Luc
Sergeant, Nicolas
Bordet, Régis
Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
title Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
title_full Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
title_fullStr Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
title_full_unstemmed Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
title_short Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
title_sort recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061923/
https://www.ncbi.nlm.nih.gov/pubmed/24944524
http://dx.doi.org/10.1186/1477-5956-12-24
work_keys_str_mv AT gelepatrick recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT vingtdeuxvalerie recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT poteycamille recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT drobecqherve recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT ghestemantoine recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT melnykpatricia recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT bueeluc recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT sergeantnicolas recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke
AT bordetregis recoveryofbrainbiomarkersfollowingperoxisomeproliferatoractivatedreceptoragonistneuroprotectivetreatmentbeforeischemicstroke